홈 › 만성 림프구성 백혈병 › 미주리
미주리의 만성 림프구성 백혈병 임상 시험
만성 림프구성 백혈병 관련 연구 13개가 미주리 내 여러 지역에서 참여자를 모집하고 있습니다.
미주리의 도시
공식 연구 텍스트(영어)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Francis Medical Center, Cape Girardeau
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- 외 11개
피험자 모집 중3상
65세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 외 21개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Francis Medical Center, Cape Girardeau
- Saint Luke's Hospital, Chesterfield
- Parkland Health Center - Farmington, Farmington
- 외 11개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT04269902A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- St Lukes Center For Cancer Care, Chesterfield
- Oncology Hematology Associates, Springfield
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Washington University School of Medicine, St Louis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Washington University School of Medicine, St Louis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06136559A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Washington University School of Medicine/Siteman Cancer Center, St Louis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT0652830164Cu-LLP2A for Imaging Hematologic Malignancies
- Washington University School of Medicine, St Louis
피험자 모집 중초기 1상건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 6. 17. 업데이트됨 · NCT06636175A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 4. 9. 업데이트됨 · NCT06428019A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Washington University, St Louis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 11. 14. 업데이트됨 · NCT05643742A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
피험자 모집 중2상
18세 ~ 80세 · 모든 성별 · 2025. 10. 14. 업데이트됨 · NCT06520098ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.